FLAG Claudin Family: comprehensive, stable, highly active proteins

The primary bottlenecks in Claudin research stem from their complex four-pass transmembrane topology and exceptionally small extracellular loops, which yield high sequence homology among family members and severely limit unique epitope availability for highly selective antibody generation. To overcome these purification hurdles and maintain protein activity, researchers employ specialized reconstitution methodologies. These include screening mild, non-denaturing detergents like DDM/CHS to stabilize the hydrophobic domains during initial extraction, as well as embedding proteins into biomimetic scaffolds like lipid nanodiscs or virus-like particles (VLPs). These lipid bilayers effectively mimic the native cell membrane environment, preventing structural collapse and preserving long-term conformational specificity.

Claudin family proteins are generally classified as channel-forming or barrier-forming based on their effects on paracellular permeability. Channel-forming Claudins, such as Claudin2, Claudin10, and Claudin15, create selective pores that facilitate the passage of ions or water across epithelial barriers. In contrast, barrier-forming Claudins, including Claudin1, Claudin3, Claudin4, Claudin5, and Claudin18, strengthen tight junctions and restrict paracellular transport, thereby maintaining tissue integrity. This functional classification is essential for understanding epithelial physiology, disease mechanisms, and the development of Claudin-targeted therapeutic strategies.

Developing therapeutic antibodies against Claudin family proteins presents several challenges. First, Claudins are highly homologous, requiring antibodies with exceptional specificity to avoid cross-reactivity among family members. Second, many Claudins are embedded within tight junctions in normal tissues, limiting epitope accessibility and increasing the importance of targeting tumor-specific exposure. Third, expression heterogeneity across tumors can affect therapeutic efficacy and patient selection. Finally, the success of antibody-based modalities depends on factors such as antigen density, internalization kinetics, and membrane localization, all of which influence the performance of monoclonal antibodies, ADCs, and bispecific antibodies.

Claudin family proteins have become attractive targets for multiple therapeutic modalities because of their tumor-associated expression patterns. Monoclonal antibodies can block signaling and induce ADCC or CDC, while antibody-drug conjugates (ADCs) selectively deliver cytotoxic payloads to Claudin-expressing tumor cells. Bispecific antibodies simultaneously engage Claudins and immune cells to enhance antitumor immunity. In addition, CAR-T cell therapies, particularly those targeting CLDN18.2 and CLDN6, have demonstrated encouraging clinical activity in solid tumors. Selecting the optimal modality depends on target accessibility, expression specificity, internalization efficiency, and the biological characteristics of each Claudin family member.

The Claudin family consists of 27 transmembrane proteins, many of which are implicated in human diseases. Claudin18.2 is associated with gastric and pancreatic cancers, Claudin6 with ovarian and testicular germ cell tumors, Claudin1 with colorectal cancer, hepatocellular carcinoma, and hepatitis C virus infection, Claudin4 with ovarian and pancreatic cancers, and Claudin10 with HELIX syndrome, a rare inherited renal disorder. In addition, Claudin16 and Claudin19 are linked to familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC). These disease associations make Claudins valuable diagnostic biomarkers and promising therapeutic targets.